Coinfection of TT virus and response to interferon therapy in patients with chronic hepatitis B or C

Yung-Chih Lai, Ruey-Tyng Hu, Sien-Sing Yang, Chi-Hwa Wu

Abstract
AIM: To investigate the serum positive percentage of TT virus (TTV) in patients with chronic hepatitis B or C and the response of the coinfected TTV to interferon (IFN) during IFN therapy for chronic hepatitis B and C.

METHODS: We retrospectively studied the serum samples of 70 patients with chronic hepatitis who had received IFN-alfa therapy from January 1997 to June 2000, which included 40 cases of hepatitis B and 30 hepatitis C. All the patients had been followed up for at least 6 months after the end of IFN therapy. The serum TTV DNA was detected using the polymerase chain reaction (PCR) before and every month during the course of IFN treatment.

RESULTS: TTV infection was detected in 15% (6/40) of the chronic hepatitis B group and 30% (9/30) of the chronic hepatitis C group. Loss of serum TTV DNA during IFN therapy occurred in 3 of 6 patients (50%) and 6 of 9 (67%) of hepatitis B and C groups, respectively. Seronegativity of TTV was found all during the first month of IFN therapy in the 9 patients. There was no correlation between the seroconversion of TTV and the biochemical changes of the patients.

CONCLUSION: TTV is not infrequently coinfected in patients with chronic hepatitis B and C in Taiwan, and more than half of the TTV infections are IFN-sensitive. However, the loss of serum TTV DNA does not affect the clinical course of the patients with chronic hepatitis B or C.

INTRODUCTION
In 1997, a novel DNA virus was isolated from a patient with post-transfusion hepatitis of unknown etiology in Japan, and was designated as TT virus (TTV) after the initials of the index patient[1]. From then on TTV has been studied worldwide. Now we know that TTV genome is non-enveloped, circular, single-stranded DNA and comprises 3,852 bases with a particle size of 30-50nm. These findings suggest that TTV is closely related to the Circoviridae[2,3].

In the original studies from Japan, the agent was found in 34/290 (12%) of healthy donors, compared to 9/91 (47%) of patients with fulminant non-A to G hepatitis and 41/90 (46%) with non-A-G chronic liver disease[4]. In 72 patients with chronic liver disease in the United Kingdom, TTV DNA was demonstrated in 18 cases (25%), compared to 10% of 30 cases of healthy controls[5]. Chronic liver disease caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is common in Taiwan[6,7] and interferon (IFN) has been used for the treatment of chronic infections. Therefore, we aimed to study the serum positive percentage of TTV infection in such patients who had received IFN therapy and also to see the response of TTV to IFN during the course of the treatment.

MATERIALS AND METHODS
Patients
We retrospectively studied the frozen-stored serum samples from the patients who had received IFN therapy for chronic hepatitis B and C at Cathay General Hospital from January 1997 to June 2000.

For chronic hepatitis B, we only included the cases with both positive HBsAg (Auszyme, Abbott Lab., North Chicago, Il.) and positive HBeAg [HBe (rDNA) EIA, Abbott Lab.]. Hepatitis C was confirmed with positive results for the anti-HCV antibody (Murex anti-HCV, version III, Murex Diagnostics Ltd., Dartford, England). All the cases had elevated serum alanine transaminase (ALT) levels exceeding 6 months and had had at least three documented occasions of levels higher than twice the upper limit of normal (<35 IU/L), at least 1 month apart, and within 6 months prior to enrollment. All the patients underwent liver biopsy within 1 month before the start of IFN treatment. The diagnosis of chronic liver disease was based on clinical and pathological results. Serum samples taken from the patients were stored at -70°C until use.

None of our patients was alcoholic, an intravenous drug abuser or homosexual. None had received hepatotoxic drugs, herbal medicine or immuno-suppressive therapy within the 6 months prior to IFN therapy. Patients with metabolic liver diseases including hemochromatosis, Wilson’s disease or alpha-1 antitrypsin deficiency and autoimmune hepatitis were excluded by clinical and laboratory examinations. None had decompensated liver function (prolonged prothrombin time > 3 seconds, serum total bilirubin > 3.0 mg/dl, or serum albumin < 3.0 gm/dl), chronic renal failure, clotting abnormalities, or serious neurological disorders. Those who coinfected with both HBV and HCV were also excluded. Informed consent for the IFN therapy and examinations, including virological assays, was obtained from all the patients.

Laboratory assays
The patients underwent blood biochemical tests every week for the initial 4 weeks and every 2 weeks thereafter during the treatment until 24 weeks. After the end of the treatment, the patients were followed up at 4-week intervals for 12 months.

Serum samples from hepatitis C patients were examined for HCV RNA using reverse transcription-nested polymerase chain reaction (PCR) with primers for the 5’-noncoding region of HCV RNA. Genotyping of HCV RNA was assayed by PCR with type-specific primers[8]. Serum HBV DNA was quantified with the use of a signal amplified solution hybridization antibody capture assay (Hybrid capture system, Digene, Gaithersburg, MD, USA). The presence of serum HCV RNA or HBV DNA was determined before the initiation of IFN therapy, at the end of therapy, and at 24 weeks after the completion of therapy.

www.wjgnet.com
Detection of TTV DNA

Serum TTV DNA was determined in specimens before the initiation of IFN therapy and regularly checked every 1 month during the course of the treatment. TTV DNA was examined using the PCR method with nested primers as previously described. Briefly, DNA was extracted from 100 µL of serum using a QIAMP blood kit (QIAGEN Ltd., Crawley, UK) and resuspended in 50 µL of elution buffer. For the first round of PCR, 25 µL of reaction mixture containing 2 µL of the cDNA sample, 1×PCR buffer (10mM tris-HCl pH 9.0, 50mM KC1, 1.5mM MgCl2, 0.01% gelatin, and 0.1% Triton X-100), 10mM of each dNTP, 100ng of each outer primer T-1 (sense: 5’-ACA GAC AGA GGA GAA GCC AAC ATG-3’) and T-2 (anti-sense: 5’-CTA CCT CTT GGC ATT TTA CC-3’), and 1 unit of Taq DNA polymerase was amplified in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) for 30 cycles. One microliter of the PCR products was re-amplified for another 30 cycles with 100ng of inner primers, T-3 (sense: 5’-GGC AAC ATG TTA TGG ATA GAC TGG-3’) and T-4 (anti-sense: CTG GCA TTT TAC TTC CAA AGT T-3’). The amplified products were separated by 3% agarose gel electrophoresis and stained with ethidium bromide.

Interferon therapy

For patients with chronic hepatitis B, 10 million units (mu) of recombinant interferon alfa-2b (Intron A, Schering-Plough, Co. Kenilworth, NJ, USA) was subcutaneously administered three times weekly for 24 weeks. For those with hepatitis C, 4.5 million units of recombinant alfa-2a (Roferon-A, F. Hoffmann-La Roche Ltd., Basle, Switzerland) was used subcutaneously three times a week for 24 weeks. The response to IFN was classified into two patterns according to the serum ALT level. Patient who had normalized serum ALT level (<35 IU/L) during therapy and remained constant for up to 6 months after the end of therapy was considered to have a biochemical sustained response. Non-sustained response was defined as serum ALT level that could not be normalized either at the end of therapy or during the follow-up period. The virological sustained response was defined as the absence of HBV DNA and HBeAg for hepatitis B, HCV RNA for hepatitis C and TTV DNA for TTV infection at 6 months after the end of therapy.

Statistical analysis

Data were analyzed by Student’s t test, Chi-squared test with Yates’ correction or Fisher’s exact test where appropriate. All statistical tests were two-sided. A P value of less than 0.05 was considered significant.

RESULTS

The sera of 70 patients were studied, which included 40 patients with chronic hepatitis B and 30 patients with chronic hepatitis C (Table 1). The difference of ages between the two groups was statistically significant (P<0.001). In those with chronic hepatitis B, the mean age was 33 years; whereas in the chronic hepatitis C group, it was 41 years. For the gender distribution and serum ALT levels, there was no statistically significant difference between the two groups.

Serum TTV DNA could be detected in 6 cases (15%) of chronic hepatitis B and 9 cases (30%) of chronic hepatitis C. However, the difference was not statistically significant (P=0.130) (Table 1).

During IFN therapy loss of serum TTV DNA was found in 3 of 6 (50%) TTV-positive patients with chronic hepatitis B and 6 of 9 (67%) TTV-positive patients with chronic hepatitis C (Table 2). Because this was a retrospective study and the doses of IFN used for chronic hepatitis B and C were different, we could not compare the rate of TTV disappearance between the two groups. Of interest, disappearance of serum TTV DNA occurred during the first 4 weeks of IFN therapy in all the 9 cases despite the regimen of treatment or the type of chronic viral hepatitis (Table 2). In addition, serum ALT levels did not change when TTV disappeared from the serum. Serum TTV DNA was still examined every 4 weeks after the cessation of IFN therapy in the 9 cases of TTV seroconversion and had continued for 24 weeks. There was no case having the re-emergence of TTV DNA during this follow-up period.

Disappearance of TTV occurred in different genotypes of chronic hepatitis C (1a: 1/1 case, 1b: 3/5 cases, 2a: 1/2 cases, 2b: 1/1 case.). However, the number of cases was small.

In the group of chronic hepatitis B, 10 patients had virological persistent response to IFN therapy, and all the 10 patients also had biochemical persistent response. Whereas, only one patient (1/3 cases) with virological persistent response of TTV DNA had biochemical persistent response (Table 3). If we further exclude the patient with concomitant loss of HBV DNA, HBeAg and TTV DNA, none of the patients (0/2 cases) with TTV virological persistent response had biochemical persistent response.

In the group of chronic hepatitis C, all the 7 patients with virological persistent response of HCV RNA to IFN therapy had biochemical persistent response, and 2 patients (2/6 cases) with virological sustained response of TTV DNA had biochemical persistent response (Table 3). Nevertheless, none of the patients (0/4 cases) of TTV virological sustained response had biochemical persistent response after exclusion of 2 patients of concomitant loss of TTV DNA and HCV RNA.

Table 1 Demographic data and serum positive percentage of TTV in the two groups

| Type          | Sex (M/F) | Age (yr)      | ALT (IU/L) | TTV DNA |
|---------------|-----------|---------------|------------|---------|
|               |           |               |            | No. Positive | %     |
| B⁺ (n=40)     | 29/11     | 33±8º         | 133±65     | 6        | 15     |
| C⁺ (n=30)     | 24/6      | 41±9          | 121±60     | 9        | 30     |
|               |           |               |            |           |       |
| B⁺            | 3         | 0             | 0          | 0        | 0      | 3     |
| C⁺            | 6         | 0             | 0          | 0        | 0      | 6     |

Data are presented as case number. *Chronic hepatitis B group. **Chronic hepatitis C group. P<0.001.

Table 2 Loss of serum TTV DNA during IFN therapy in the two groups

| Time of IFN Therapy (weeks) | Total |
|-----------------------------|-------|
| 4                           | 8     |
| 12                          | 16    |
| 20                          | 24    |
|                             |       |
| B⁺                          | 3     |
| C⁺                          | 6     |

Table 3 Relationship between viral and biochemical responses in the group of chronic hepatitis B

| Virological SR | HBV (n=10) | TTV (n=3) |
|---------------|------------|-----------|
| Biochemical SR (+) | 10        | 1         |
| Biochemical SR (-)  | 0         | 2         |
| SR: sustained response, P=0.038, by Fisher’s exact test |

Table 4 Relationship between viral and biochemical responses in the group of chronic hepatitis C

| Virological SR | HCV (n=7) | TTV (n=6) |
|---------------|-----------|-----------|
| Biochemical SR (+) | 7        | 2         |
| Biochemical SR (-)  | 0        | 4         |
| SR: sustained response, P=0.021, by Fisher’s exact test |
Coinfection of TTV has been observed frequently in patients for the detection of TTV DNA. These results imply that HBV, HCV, chronic hepatitis C according to the recently published reports[18-20], IFN therapy was detected to be 40-55% in patients coinfected with serum TTV DNA at 24 weeks after the end of IFN therapy for that 41% (17/41) of patients with HCV and TTV coinfection lost hepatitis B, C and D[22-26]. However, because the causal role of TTV in the efficacy of recombinant interferon-alfa for patients with chronic hepatitis C, and the range was 20-46%[18-20]. The variation might be due to the different primers used for the detection of TTV DNA. These results imply that HBV, HCV, and TTV may share common modes of transmission[19].

The interferons possess antiproliferative, antiviral and immunomodulant properties[21]. Extensive clinical trials have confirmed the efficacy of recombinant interferon-alfa for patients with chronic hepatitis B, C and D[10-20]. However, because the causal role of TTV in liver disease has not been established, there is only a few papers which studied the response of TTV to IFN therapy. Taking advantage of previous research of IFN therapy for chronic hepatitis B and C, we were able to retrospectively study the prevalence of TTV in these patients and to see the response of TTV to IFN treatment. In our study, loss of serum TTV DNA during IFN therapy was noted in 50% (36/72) of patients with HBsAg (+) and 36% of 10 patients with HCV RNA (+) had TTV infection[17]. Several other studies also reported that the serum positive rates of TTV DNA in the patients with chronic hepatitis C, and the range was 20-46%[18-20]. The variation might be due to the different primers used for the detection of TTV DNA. These results imply that HBV, HCV, and TTV may share common modes of transmission[19].

The interferons possess antiproliferative, antiviral and immunomodulant properties[20]. Extensive clinical trials have confirmed the efficacy of recombinant interferon-alfa for patients with chronic hepatitis B, C and D[10-20]. However, because the causal role of TTV in liver disease has not been established, there is only a few papers which studied the response of TTV to IFN therapy. Taking advantage of previous research of IFN therapy for chronic hepatitis B and C, we were able to retrospectively study the prevalence of TTV in these patients and to see the response of TTV to IFN treatment. In our study, loss of serum TTV DNA during IFN therapy was noted in 50% (36/72) of patients with HBsAg (+) and 36% of 10 patients with HCV RNA (+) had TTV infection[17]. Several other studies also reported that the serum positive rates of TTV DNA in the patients with chronic hepatitis C, and the range was 20-46%[18-20]. The variation might be due to the different primers used for the detection of TTV DNA. These results imply that HBV, HCV, and TTV may share common modes of transmission[19].

In summary, the serum positive percentage of TTV in chronic hepatitis B or C in our series was not low. During the IFN therapy for chronic hepatitis B or C, disappearance of coinfected TTV occurred in more than half of the patients. IFN-sensitive TTV usually lost its DNA during the first month of treatment. Genotyping of TTV might further clarify the cause of diverse responses to IFN therapy. The finding that the disappearance of TTV DNA did not affect the clinical course of chronic hepatitis favors the null hypothesis of no significant association of TTV with liver disease.

REFERENCES

1. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun 1997; 241:92-97.
2. Okamoto H, Nishizawa T, Kato N, Ukitaka M, Ikeda H, Iizuka H. Molecular cloning and characterization of a novel DNA virus (TTV) associated with posttransfusion hepatitis of unknown etiology. Hepatology Research 1998; 10:1-16.
3. Mushahwar IK, Erker JC, Muerhoff AS, Leary TP, Simon JN, Birkenmeyer LG. Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans. Proc Natl Acad Sci USA 1999; 96:3177-3182.
4. Naoumov N, Petrova EP, Thomas MG, Williams R. Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet 1998; 352:195-197.
5. Chen DS. Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K, Ishak KG, editors. Neoplasm of the liver. Tokyo: Springer Verlag 1987: 71-80.
6. Chen DS, Kao G, Sung JL, Lai MY, Sheu JC, Chen PJ. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1995; 162:817-822.
7. Kao JH, Chen PJ, Yang PM, Lai MY, Sheu JC, Wang TH. Interfamilial transmission of hepatitis C virus: the important role of infections between spouses. J Infect Dis 1992; 166:900-903.
8. Kao JH, Chen W, Hsiung SC, Chen PJ, Lai MY, Chen DS. Prevalence and implication of TTV infection: minimal role in patients with non-A-E hepatitis in Taiwan. J Med Virol 1999; 59:307-312.
9. Yang SS, Wu CH, Chen TH, Huang YH, Huang CS. TTV viral infection through blood transfusion: retrospective investigation on patients in a prospective study of post-transfusion hepatitis. World J Gastroenterol 2000; 6:53-56.
10. Desai SM, Muerhoff AS, Leary TP. Prevalence of TTV infection in US blood donors and populations at risk for acquiring parenterally transmitted viruses. J Infect Dis 1999; 179:1242-1244.
11. MacDonald DM, Scott GR, Clutterbuck D. Infrequent detection of TTV infection in intravenous drug users, prostitutes, and homosexual men. J Infect Dis 1999; 179:686-689.
12. Hohne M, Berg T, Muller AR, Schreier E. Detection of sequences of TT virus, a novel DNA virus, in German patients. J Gen Virol 1999; 79:2753-2761.
13. Poovorawan Y, Themboonlers A, Jantaradansri P, Kaew-in N, Hirsh P, Tangkitvanich P. Hepatitis TT virus infection in high-risk groups.
14 Takayama S, Yamazaki S, Matsuo S, Sugii S. Multiple infection of TT virus (TTV) with different genotypes in Japanese hemophiliacs. Biochem Biophys Res Commun 1999; 256: 208-211
15 Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Galloini A, Ruot A. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105:1529-1533
16 Kao JH, Chen W, Chen PJ, Lai MY, Chen DS. TT virus infection in patients with chronic hepatitis B or C: influence on clinical, histological and virological features. J Med Virol 2000; 60: 387-392
17 Tanaka H, Okamoto H, Luengrojanakul P, Chainuvati T, Tsuda F, Tanaka T. Infection with an unenveloped DNA virus (TTV) associated with posttransfusion non-A to G hepatitis in hepatitis patients and healthy blood donors in Thailand. J Med Virol 1998; 56: 234-238
18 Watanabe H, Saito T, Kawamata O, Shao L, Aoki M, Terui Y. Clinical implication of TT virus superinfection in patients with chronic hepatitis C. Am J Gastroenterol 2000;95:1776-1780
19 Akahane Y, Sakamoto M, Miyazaki Y, Okada S, Inoue T, Ukita M. Effect of interferon on a nonenveloped DNA virus (TT virus) associated with acute and chronic hepatitis of unknown etiology. J Med Virol 1999;58:196-200
20 Hagiwara H, Hayashi N, Mita E, Oshita M, Kobayashi I, Iio S. Influence of transfusion-transmitted virus infection on the clinical features and response to interferon therapy in Japanese patients with chronic hepatitis C. J Viral Hepat 1999;6:463-469
21 Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266: 1375-1383
22 Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994; 39:241-275
23 Woo MH, Burnakas TG. Interferon alfa in the treatment of chronic viral hepatitis B and C. Ann Pharmacother 1997; 31: 330-337
24 Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J. A randomized controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88:1887-1892
25 Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462
26 Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993; 38: 612-618
27 Chayama K, Kobayashi M, Tsubota A, Kobayashi M, Arase Y, Suzuki Y. Susceptibility of TT virus to interferon therapy. J Gen Virol 1999;80: 631-634
28 Kanda T, Yokosuka O, Ikeuchi T. The role of TT virus infection in acute viral hepatitis. Hepatology 1999; 29: 1905-1908.Utsunomiya S, Yoshio K, Wakita T, Seno H, Takagi K, Ishigami M. TT virus infection in hemodialysis patients. Am J Gastroenterol 1999; 94: 3567-3570

Edited by Zhang JZ